GD2-CART01 for Relapsed or Refractory High-Risk Neuroblastoma
New England Journal of Medicine · 06.04.2023 · 388 (14) · 1284-1295
DOI: 10.1056/nejmoa2210859 ↗Kurz gefasst
Fachartikel in der Zeitschrift New England Journal of Medicine, erschienen am 06.04.2023. Verfasst von Francesca Del Bufalo und 35 weiteren Autor:innen. Beteiligte Einrichtung: From the Department of Pediatric Hematology and Oncology and of Cell and Gene Therapy (F.D.B., B.D.A., I.C., G.D.B., M.A.D.I., A.S., A.M., M.G.C., D.…. Hauptthemen laut MEDLINE: Immunotherapy, Adoptive, Neuroblastoma, Receptors, Chimeric Antigen. Die Arbeit wurde bisher 589-mal zitiert (Crossref) und nennt 32 Literaturangaben. Gefördert von: Italian Medicines Agency–Ricerca Indipendente, Italian Ministry of Health, Associazione Italiana per la Ricerca sul Cancro.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- From the Department of Pediatric Hematology and Oncology and of Cell and Gene Therapy (F.D.B., B.D.A., I.C., G.D.B., M.A.D.I., A.S., A.M., M.G.C., D.P., M. Amicucci, G.L.P., V.B., M.S., S.D.C., M. Guercio, Z.A., L.I., M…
ORCID-Profile: Ignazio Caruana, Maria A De Ioris, Franco Locatelli
Förderung
- Italian Medicines Agency–Ricerca Indipendente
- Italian Ministry of Health
- Associazione Italiana per la Ricerca sul Cancro
- Innovative Medicines Initiative 2 Joint Undertaking
- Lazio Innova Project Immunotherapy Approaches
- Project CAR for Sarcoma
- Fondazione Neuroblastoma
- Italian Piano Nazionale di Ripresa e Resilienza CN3
Zitieren
APA
Del Bufalo, F., De Angelis, B., Caruana, I., Del Baldo, G., De Ioris, M. A., Serra, A., Mastronuzzi, A., Cefalo, M. G., Pagliara, D., Amicucci, M., Li Pira, G., Leone, G., Bertaina, V., Sinibaldi, M., Di Cecca, S., Guercio, M., Abbaszadeh, Z., Iaffaldano, L., Gunetti, M., …, & Precision Medicine Team–IRCCS Ospedale Pediatrico Bambino Gesù (2023). GD2-CART01 for Relapsed or Refractory High-Risk Neuroblastoma. New England Journal of Medicine, 388(14), 1284-1295. https://doi.org/10.1056/nejmoa2210859
Vancouver
Del Bufalo F, De Angelis B, Caruana I, Del Baldo G, De Ioris MA, Serra A, et al. GD2-CART01 for Relapsed or Refractory High-Risk Neuroblastoma. New England Journal of Medicine. 2023;388(14):1284-1295. doi:10.1056/nejmoa2210859
BibTeX
@article{DelBufalo2023,
author = {Del Bufalo, Francesca and De Angelis, Biagio and Caruana, Ignazio and Del Baldo, Giada and De Ioris, Maria A and Serra, Annalisa and Mastronuzzi, Angela and Cefalo, Maria G and Pagliara, Daria and Amicucci, Matteo and Li Pira, Giuseppina and Leone, Giovanna and Bertaina, Valentina and Sinibaldi, Matilde and Di Cecca, Stefano and Guercio, Marika and Abbaszadeh, Zeinab and Iaffaldano, Laura and Gunetti, Monica and Iacovelli, Stefano and Bugianesi, Rossana and Macchia, Stefania and Algeri, Mattia and Merli, Pietro and Galaverna, Federica and Abbas, Rachid and Garganese, Maria C and Villani, Maria F and Colafati, Giovanna S and Bonetti, Federico and Rabusin, Marco and Perruccio, Katia and Folsi, Veronica and Quintarelli, Concetta and Locatelli, Franco and Precision Medicine Team–IRCCS Ospedale Pediatrico Bambino Gesù, Precision Medicine Team–IRCCS Ospedale Pediatrico Bambino Gesù},
title = {GD2-CART01 for Relapsed or Refractory High-Risk Neuroblastoma},
journal = {New England Journal of Medicine},
year = {2023},
volume = {388},
number = {14},
pages = {1284--1295},
doi = {10.1056/nejmoa2210859}
}
EUVIMED